Skip Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
  Division of Sexually Transmitted Diseases
    Program and Training Branch
STD Prevention STD Training Home Links Contact Us Glossary 
Skip Navigation Links
Self-Study Modules
Vaginitis
Course Objective
Line separator
Target audience
Line separator
Continuing education
Lessons
Line separator
Introduction
Line separator
Diagnosis and Evaluation
Line separator
Trichomoniasis
Line separator
Candidiasis
Line separator
Epidemiology
Line separator
Pathogenesis and microbiology
Line separator
Clinical manifestations and sequelae
Line separator
Diagnostic methods
Line separator
Patient management / treatment
Line separator
Prevention
Line separator
Bacterial Vaginosis (BV)
Line separator
Case study
Line separator
Resources
Line separator
Self-Study STD Module - Vaginitis : Candidiasis

Patient Management/Treatment

Patient management and treatment of VVC depends on the clinical presentation, microbiology, host factors, and response to therapy. Vulvovaginal candidiasis can be classified as uncomplicated or complicated.

Classification of Vulvovaginal Candidiasis
   Uncomplicated VVC
  • Sporadic or infrequent vulvovaginal candidiasis
    Or
  • Mild-to-moderate vulvovaginal candidiasis
    Or
  • Likely to be C. albicans
    Or
  • Non-immunocompromised women
   Complicated VVC
  • Recurrent vulvovaginal candidiasis (RVVC)
    Or
  • Severe vulvovaginal candidiasis
    Or
  • Non-albicans candidiasis
    Or
  • Women with uncontrolled diabetes, debilitation, or immunosuppression or those who are pregnant

Treatment for Uncomplicated VVC

The CDC-recommended treatment regimens for uncomplicated VVC include intravaginal agents and oral agents as well as over-the-counter therapeutics and prescription drugs. Uncomplicated VVC responds to all azole treatment regimens including short (3-day) and single-dose oral and vaginal therapy.

   Intravaginal agents:
  • Butoconazole 2% cream, 5 g intravaginally for 3 days†
    OR
  • Butoconazole 2% sustained release cream, 5 g single intravaginally application
    OR
  • Clotrimazole 1% cream 5 g intravaginally for 7-14 days†
    OR
  • Clotrimazole 100 mg vaginal tablet for 7 days
    OR
  • Clotrimazole 100 mg vaginal tablet, 2 tablets for 3 days
    OR
  • Miconazole 2% cream 5 g intravaginally for 7 days†
    OR
  • Miconazole 100 mg vaginal suppository, 1 suppository for 7 days†
    OR
  • Miconazole 200 mg vaginal suppository, 1 suppository for 3 days†
    OR
  • Miconazole 1,200 mg vaginal suppository, 1 suppository for 1 days†
    OR
  • Nystatin 100,000-unit vaginal tablet, 1 tablet for 14 days
    OR
  • Tioconazole 6.5% ointment 5 g intravaginally in a single application†
    OR
  • Terconazole 0.4% cream 5 g intravaginally for 7 days
    OR
  • Terconazole 0.8% cream 5 g intravaginally for 3 days
    OR
  • Terconazole 80 mg vaginal suppository, 1 suppository for 3 days
   Oral agent:
  • Fluconazole 150 mg oral tablet, 1 tablet in a single dose

† Over-the-counter (OTC) preparations.

Page 15 of 26 BackStatusStatusNext


STD Home
| STD Index

CDC Home | Search | Health Topics A-Z

Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
     Division of Sexually Transmitted Diseases Prevention